NCT02383355View on ClinicalTrials.gov

Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 1, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

July 1, 2017

Conditions
HIV
Interventions
DRUG

Raltegravir

Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy

DRUG

Continuation of own regimen

Continuation of own antiretroviral medication during the 10 weeks follow-up

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Radboud University Medical Center

OTHER

NCT02383355 - Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation | Biotech Hunter | Biotech Hunter